Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TumorGlow
NCT03262636Phase 1Completed
- Sponsor
- University of Pennsylvania
- Start
- Jun 2015
- Primary completion
- Mar 2020
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of indocyanine green in brain tumor (2 arms), sponsored by University of Pennsylvania. Primary endpoint: Sensitivity of ICG uptake and expression in identifying ANS tumor deposits at 36 months. Started Jun 2015; status: completed.
02
Drugs
indocyanine green
03
Conditions
brain tumor
Beyond the preview
Go deeper on NCT03262636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03262636.